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Background: Amyloid plaques and neurofibrillary tangles (NFTs) are the defining pathological hallmarks of
Alzheimer’s disease (AD). Increasing the quantity of the O-linked N-acetylglucosamine (O-GlcNAc) post-translational
modification of nuclear and cytoplasmic proteins slows neurodegeneration and blocks the formation of NFTs in a
tauopathy mouse model. It remains unknown, however, if O-GlcNAc can influence the formation of amyloid plaques
in the presence of tau pathology.
Results: We treated double transgenic TAPP mice, which express both mutant human tau and amyloid precursor
protein (APP), with a highly selective orally bioavailable inhibitor of the enzyme responsible for removing O-GlcNAc
(OGA) to increase O-GlcNAc in the brain. We find that increased O-GlcNAc levels block cognitive decline in the
TAPP mice and this effect parallels decreased β-amyloid peptide levels and decreased levels of amyloid plaques.
Conclusions: This study indicates that increased O-GlcNAc can influence β-amyloid pathology in the presence of
tau pathology. The findings provide good support for OGA as a promising therapeutic target to alter disease
progression in Alzheimer disease.
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The formation of oligomers and aggregates of β-amyloid
peptides derived from amyloid precursor protein (APP) is
a causative early factor giving rise to Alzheimer Disease
(AD) [1-3]. Neuritic plaques are the pathological feature
associated with deposition of large aggregates of β-
amyloid peptides. Mutations in the human APP gene can
give rise to autosomal dominant early-onset forms of AD,
which resemble late-onset AD (hereafter simply AD) both
clinically and at the histopathological level [4-6]. Further-
more, some mutations in APP also confer protection
against AD [7]. The deleterious APP mutations driving* Correspondence: dvocadlo@sfu.ca
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unless otherwise stated.early-onset AD appear sufficient to promote, within
humans, the formation of the other classical pathological
hallmark of AD known as the neurofibrillary tangles
(NFTs). NFTs are formed as a result of the self assembly
of hyperphosphorylated microtubule-associated protein
tau into paired helical filaments (PHFs) which then aggre-
gate into larger structures known as NFTs [8-11]. Human
mutations in the tau gene (MAPT), on their own, can also
give rise to a group of neurodegenerative diseases referred
to as frontotemporal dementia linked to chromosome-17
(FTDP-17), one group of a number of different types of
tauopathy [12,13]. However, human MAPT mutations do
not cause the formation of neuritic plaques, thereby lend-
ing significant support for β-amyloid peptide formation as
a factor upstream of tau in AD.
Studying the relationship between NFTs and neuritic
plaques in AD is complicated by the fact that rodent
models that carry human APP mutations do not generallyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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presence of neuritic plaques and cognitive impairment.
Conversely, mouse models that express human MAPT
mutations, such as the P301L mutant expressing JNPL3
mice, do not produce neuritic plaques [16]. For this reason
several groups have developed mouse models of AD that
recapitulate both pathological features of AD. One model,
generated by Lewis et al., referred to as the TAPP mouse,
resulted from crosses of JNPL3 tau mice with mice express-
ing the most common APP mutant (Swedish mutation
K670N/M671L, APPSwe; Tg2576) [17]. Differing from the
parent single transgenic models, TAPP mice brains contain
both plaques and NFTs. Notably, these TAPP mice display
enhanced tau pathology as compared to JNPL3 mice, sug-
gesting that β-amyloid peptides accelerate the formation of
NFTs [17], a proposal supported by other studies involving
intracerebral injection of β-amyloid Aβ42 fibrils into P301L
tau transgenic mice [18]. The TAPP mouse model is there-
fore well suited to study therapeutic strategies that might
impact neuritic plaques or NFT formation in a setting that
captures these two synergistic pathologies.
Previously, we reported a potential disease modifying
approach aimed at reducing toxicity associated with tau
aggregation and NFT formation. This approach involved
increasing global levels of a little-studied post-translational
modification known as the O-GlcNAc modification [19].
Chronic increases in the levels of O-GlcNAc modification
in JNPL3 mouse brains and spinal cords slowed neur-
onal loss and reduced the number of NFTs formed over
a treatment period of several months [20]. O-GlcNAc
modification of proteins involves the attachment of sin-
gle N-acetyl-D-glucosamine residues to the hydroxyl
side chains of serine and threonine residues of proteins
[19]. The O-GlcNAc modification differs from classical
forms of glycosylation found on the outside of the cell
and within the secretory pathway because O-GlcNAc is
found in the nucleocytoplasm and it does not have add-
itional sugar residues attached to it to form more complex
structures [19]. The fact that O-GlcNAc can be added or
removed from a particular protein multiple times during
the lifespan of the protein makes it a dynamic modification
[21] somewhat akin to protein phosphorylation, which is
likewise reversible. Installation of O-GlcNAc on serine or
threonine is carried out by a single glycosyltransferase re-
ferred to as O-GlcNAc transferase (OGT), which uses the
high-energy donor sugar uridine 5’-diphospho-N-acetyl-D-
glucosamine (UDP-GlcNAc) as its substrate [22,23]. A sin-
gle glycoside hydrolase, O-GlcNAcase (OGA), is tasked
with the hydrolytic cleavage of O-GlcNAc from modified
proteins [24,25]. To increase global O-GlcNAc levels in
JNPL3 mice we made use of a potent (Ki =21 nM) and se-
lective (37000-fold for human OGA over functionally re-
lated human β-hexosamindases) inhibitor of OGA referred
to as Thiamet-G, which blocks removal of O-GlcNAc frommodified proteins [26]. Thus, even as OGA is inhibited,
OGTcan continue adding O-GlcNAc onto to modified pro-
teins resulting in elevated O-GlcNAc within cells [26,27].
We previously showed that increasing O-GlcNAc
levels has beneficial effects in the JNPL3 mouse model
of tauopathy [20]. Recently APP has been found to be
O-GlcNAc modified and one study suggested that O-
GlcNAc might alter β-amyloid production by regulating
APP processing [28,29]. To study the role of O-GlcNAc
on APP and β-amyloid production in mice exhibiting both
tau and β-amyloid pathologies, we undertook a long-term
study using Thiamet-G to increase the global levels of O-
GlcNAc in TAPP mice. Here we show that Thiamet-G
can increase O-GlcNAc levels in the TAPP mouse brain,
leading to reductions in levels of both neuritic plaques
and amyloidogenic β-amyloid peptides. Consistent with
these findings we also find that Thiamet-G treatment
blocks the onset of cognitive impairment in these animals.
We also show, using cell models of β-amyloid peptide
formation, that Thiamet-G does not alter the release of
β-amyloid peptides from cells, suggesting that increased
O-GlcNAc levels in mice mediate protection against
β-amyloid peptides through a mechanism that is likely
independent of Aβ42 release.
Results
Thiamet-G treatment improves performance in the Morris
water maze (MWM)
To assess whether increased O-GlcNAc can influence
amyloid deposition or cognitive impairment in bigenic
TAPP mice, we divided 60 double transgenic TAPP mice
into three groups (n = 20) receiving either 0, 200, or 500
mkd of Thiamet-G in their drinking water. We have pre-
viously shown oral Thiamet-G treatment of mice over a
period of months leads to sustained O-GlcNAc increases
in the brains of mice [20]. Parental transgenic Tg2576
mice, which harbor only the APPSwe mutation, develop
pronounced memory impairment starting at 6 months
of age [15,30] as judged by performance in the Morris
water maze (MWM). Therefore to determine whether
increased O-GlcNAc can influence disease progression in
TAPP mice we started dosing with Thiamet-G at 10-13
weeks of age and continued until 44-47 weeks of age. Ef-
fects of OGA inhibition on cognitive impairment were
assessed by performing MWM testing on each of the ani-
mals in the three groups starting between 28-32 weeks of
age. All data acquisition and data entry was performed
blinded with the coding being held by non-experimenters.
We find that in the acquisition phase, during which animals
engage in spatial learning, the latency to solve the maze
was not significantly different between the groups as judged
by RM-ANOVA (F5,78 = 0.668, p =0.649) (Figure 1A). Dif-
ferences in the distance traveled within the maze during
this learning phase were significantly different (F5,78 =
Figure 1 Thiamet-G prevents cognitive decline in the TAPP mice. A, B. Beginning at 30-32 weeks of age 0, 200 or 500 mkd Thiamet-G treated
TAPP mice were tested for cognitive performance in the Morris water maze (MWM). Learning curves were recorded during five consecutive days of
training. No significant difference was observed between any of the groups in latency to solve the maze (A) and while a significant main effect
was noted by the ANOVA for distance travelled, the post-hoc Tukey’s analysis revealed that there were no significant differences between
groups. (B). C. During the probe trial, the latency to solve the maze was recorded and the control TAPP mice (0 mkd Thiamet-G) show
significant cognitive impairment compared to untreated age-matched wild-type mice. Conversely, 500 mkd resulted in better performance than the 0
mkd Thiamet-G treated TAPP mice while the performance of 200 mkd TAPP mice is indistinguishable from the untreated age-matched wild-type mice.
D. No differences were observed in the distance travelled during the probe trial. Error bars represent standard deviation (± S.D) and p-value result from
a one-way analysis of variance (ANOVA) For all panels, n =8 for 0 mkd wild-type mice, n =17 for 0 mkd TAPP mice, n =17 for 500 mkd TAPP mice and
n =19 for 200 mkd TAPP mice.
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not reveal any specific differences between groups
(Figure 1B). To clarify whether behavioural changes
that might be observed in these studies are due to cog-
nition per se and not due to motor differences between
groups, we examined the time spent in the outer ring
as a measure of anxiety and swim speed during these
acquisition trials. The swim speed was significantly dif-
ferent between groups (F5,78 = 2.817, p =0.022), with
the Tukey’s post-hoc analysis indicating that the 500
mkd Thiamet-G treated group was faster than the un-
treated wild-type control group (p =0.042), perhaps be-
cause treatment protects against neurodegeneration of
motor neurons as previously observed in JNPL3 mice [16].
There was no difference between the groups in the time
spent in the outer ring (F5,78 = 0.758, p =0.582) indicating
the animals showed no apparent anxiety effects.
During the probe trials, where memories formed dur-
ing the acquisition phase are tested, the 500 mkd
Thiamet-G group spent significantly more time over the
original platform location (F5,57 = 2.835, p =0.024) than
did the untreated TAPP mice (p =0.03, Tukey’s post-hocanalysis) and the same amount of time as compared to
wild-type control mice (Figure 1C), indicating increased
O-GlcNAc blocks cognitive impairment in TAPP mice.
Because the goal of the probe trial is for the animals to lo-
cate and remain within a very small area within the pool
(~25 cm2), the differences between the 500 mkd Thiamet-
G and the untreated TAPP mice are unlikely to result
from motor differences between these groups. Consistent
with this view, we did not observe any difference in the
distance travelled during the probe trial (Figure 1D). These
data indicate treatment with Thiamet-G resulted in cogni-
tive enhancement compared to untreated animals, to a
level matching that of wild-type animals.
Thiamet-G increases O-GlcNAc but does not impact tau
phosphorylation
To better understand how Thiamet-G prevents impairment
of cognitive performance, we first verified that O-GlcNAc
levels were increased in treated animals (Figure 2). Im-
munoblotting with O-GlcNAc antibodies CTD110.6 and
RL2 revealed dramatically increased O-GlcNAc levels in
both the 200 and 500 mkd treated TAPP mice compared to
Figure 2 O-GlcNAc levels are increased in the TAPP mouse brain. A. Western blots of total brain homogenates from 0, 200 and 500 mkd
Thiamet-G treated TAPP mice reveals that O-GlcNAc levels are vastly increased (RL2 and CTD110.6) while actin indicates equal protein loading.
B. Quantification of O-GlcNAc immunoreactivity (CTD110.6) normalized to actin by densitometry of all bands (left panel) or only the low molecular
weight (MW) bands (bands <50 kDa, right panel). N =10 in each group. *indicates p <0.05, ***indicates p <0.001, unpaired two-tailed t-test)
C. Immunohistochemical (IHC) analysis of 0 and 500 mkd Thiamet-G treated TAPP mice brain tissue reveals that O-GlcNAc levels are increased in
all of the hippocampus (A’, E’), cerebellum (B’, F’), pons (C’, G’) and the amygdala (D’, H’).
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densitometric quantification of the O-GlcNAc immunore-
activity of the CTD110.6 antibody based on either all of the
immunoreactive bands or only the low molecular weight
(<50 kDa) immunoreactive bands (Figure 2B). This analysis
revealed a trend toward lower O-GlcNAc levels in the 200
mkd TAPP mice group compared to the 500 mkd TAPP
mice group when considering all of the immunoreactive
bands. When only the low molecular weight bands are con-
sidered, O-GlcNAc levels were roughly 20% lower in the
200 mkd TAPP mice (p <0.05). These analyses reveal that
there is a dose dependent effect of Thiamet-G on the levels
of O-GlcNAc. We also performed immunohistochemistry
(IHC) using the O-GlcNAc antibodies (CTD110.6 and
RL2) on animals from the 0 and 500 mkd Thiamet-G
treatment groups. The hippocampus and the cerebelleum
have been previously shown to have high levels of expres-
sion of both OGA and OGT [31,32] and O-GlcNAc levels
in these structures, along with the pons and the amygdala,
were particularly increased in the 500 mkd Thiamet-G
treatment group (Figure 2C). Previously, we have shown
that Thiamet-G does not block tau hyperphosphorylation
in the transgenic parental JNPL3 mouse model [20]. We
confirmed that this was also the case in the double trans-
genic TAPP mice by immunoblot (Figure 3A) and IHC
(Figure 3B) analyses using various phosphorylation state-
specific tau antibodies. Even though dramatically increasedO-GlcNAc levels were observed (Figure 2) immunoblot
analyses revealed that Thiamet-G treatment actually
slightly increased the total amount of tau (92e) and the ex-
tent to which tau was phosphorylated but this did not
reach statistical significance. In our previous study of
JNPL3 mice [20], we found that Thiamet-G treatment re-
duced the amount of sarkosyl insoluble tau, which is known
to correlate with the amount of fibrillar tau in 9 month
old mice JNPL3 mice [33]. In a blinded experiment we
therefore probed whether Thiamet-G can also reduce the
amount of sarkosyl insoluble tau in the double transgenic
TAPP mice. We observed a strong trend of less sarkosyl
insoluble tau in the 500 mkd Thiamet-G treatment group
(32% reduction), which was consistent in magnitude with
our earlier JNPL3 study, although this difference did not
reach statistical significance in the TAPP mice (Figure 4).
Thiamet-G treatment reduces the number of amyloid
plaques and reduces Aβ levels
Previous work has shown that at 7-8 months of age the
single transgenic JNPL3 mice generally perform no worse
than age matched wild-type control animals in the MWM
[34]. For this reason, and the absence of significant effects
on tau phosphorylation, we felt that the cognitive effects
of OGA inhibition in this TAPP model reflected in the
MWM results may stem from effects of Thiamet-G treat-
ment on accumulation of β-amyloid peptides and be
Figure 3 Thiamet-G does not alter total tau or phospho-tau levels in the TAPP mice. A. Total tau (92e) blots indicate that levels of total tau
are not altered by Thiamet-G treatment. Western blots using phosphorylation state sensitive tau antibodies, pS199/pS202, pT205, pT212, pT214,
pT217, pT231, pS262/pS356, pS396, and pS396/pS404 indicate that levels of phospho-tau are also not significantly altered. Quantification by
densitometry of each total or phospho-tau epitope is shown to the right. Phospho-tau immunoreactivity is normalized to total tau (92e) in each
case. N =10 in each group. B. IHC analysis using phosphorylation state sensitive tau antibodies, pS199/pS202, pS396, pS396/pS404, pT231, pS262/
pS356 indicate that levels of phospho-tau are also not significantly altered in the hippocampus, the amygdala, or the pons in either of the 200 or
500 mkd Thiamet-G treated TAPP mice groups. Error bars represent standard error of the mean (± S.E.M).
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address this possibility we performed a number of experi-
ments in which the experimenter was blinded using coded
samples. The first study established whether Thiamet-
G had any impact on the quantities of the amyloido-
genic forms of β-amyloid 1-40 and 1-42 (Aβ40, Aβ42).
Using widely used commercially available ELISA assays
for Aβ40 and Aβ42, we determined that administration
of 500 mkd Thiamet-G significantly reduced the quan-
tity of Aβ42 while the 200 mkd treatment had no sig-
nificant effect on this measure (Figure 5). We also
observed a trend toward less Aβ40 in the 500 mkd
treatment group that was not present in the 200 mkd
group (Figure 5). As described above, O-GlcNAc levels
in the 200 mkd group are slightly lower than the 500
mkd group and thus may indicate that a sustained in-
crease in O-GlcNAc levels above a certain threshold
must be reached in order to influence the levels of Aβ
peptides within brain.
Finally, we evaluated whether the reduced Aβ42 levels
correlated with fewer amyloid plaques within these ani-
mals. By quantitative analysis, we observed fewer amyl-
oid plaques in both cortical and hippocampal regions of
the brain in the 500 mkd Thiamet-G treated group(Figure 6). Interestingly however, in the cortex we found
that 200 mkd was sufficient to reduce the number of
amyloid plaques to the same level as seen in mice
treated with 500 mkd Thiamet-G despite this dose be-
ing unable to significantly reduce levels of Aβ42 as
assessed by ELISA (Figure 6B). It is interesting to note
that O-GlcNAc levels are generally higher in the
hippocampus (Figure 2C) than in the cortex, yet we
observe larger reductions in the number of plaques in
cortex in both dose groups than observed in the hippo-
campus. Perhaps different brain regions have differing
capacities to increase O-GlcNAc levels and this may be
coupled to tissue dependent differences in amyloid de-
position that depend on O-GlcNAc levels. Further, per-
haps differences in the levels of Aβ42 within certain
brain regions are also present yet were not detected
here because the ELISAs are conducted on homoge-
nates obtained from complete brain hemispheres.
Using whole brain homogenates might mask small
differences in Aβ42 levels present in certain brain
regions. These observations suggest that increased O-
GlcNAc could influence both β-amyloid peptide pro-
duction or clearance as well as assembly/clearance of
amyloid plaques arising from Aβ42.
Figure 4 500 mkd Thiamet-G may reduce sarkosyl-insoluble tau
in the TAPP mice. Levels of sarkosyl-insoluble tau were assessed by
Western blot analysis in both the 0 and 500 mkd Thiamet-G treated
TAPP mice groups and indicated a strong trend towards less
sarkosyl-insoluble tau in the 500 mkd group. Error bars represent
standard error of the mean (± S.E.M) and p-values result from a
student’s unpaired one-tailed t-test. N =18 (Control) and n =17
(500 mkd Thiamet-G).
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from cells
In an effort to address the question of how O-GlcNAc
might affect β-amyloid peptide formation we turned to
using a well-established cell culture model used to evaluate
molecular pathways influencing APP processing [35-38].
Using a cellular model enables us to ascertain the effects ofFigure 5 Aβ40 and Aβ42 levels. ELISA assays for Aβ40 and Aβ42 were us
mkd Thiamet-G treated TAPP mice groups. A. 500 mkd was sufficient to re
B. 500 mkd Thiamet-G also showed a trend toward less Aβ40 which was n
the mean (± S.E.M) and p-values result from student’s unpaired two-tailed
TAPP mice and N =13 for 200 mkd TAPP mice.OGA inhibition on β-amyloid peptide release independent
of other factors that could obscure such effects in animals,
such as β-amyloid peptide clearance and sequestration into
plaques. The 20E2 cells we used are an established HEK
cell line stably expressing APPSwe. The mutant APPSwe is
processed by endogenous α, β and γ-secretase enzymes
leading to abundant and readily detectable release of Aβ42
(Figure 7A) as compared to untransfected HEK cells
(Figure 7B). We treated this 20E2 cell line with 100 μM
Thiamet-G overnight and in the morning provided fresh
media while maintaining 100 μM Thiamet-G. This dose of
Thiamet-G selected for use in culture studies was chosen
because we have previously found this dose to be well
beyond the saturation point of increased O-GlcNAc levels
in PC-12 cells [26] suggesting that O-GlcNAc levels are
highly elevated, which should therefore stimulate possible
effects within cells during these experiments. The cells
and culture media were collected at 4, 8 and 24 hours
after changing the media. While we were able to detect
significant accumulation of Aβ42 over time as compared
to non-transfected HEK cells, Thiamet-G did not exert
any influence on release of Aβ42. We further verified that
O-GlcNAc levels were increased at all time points in this
experiment (Figure 7C). These data suggest that there are
no differences in the rate of production or clearance of
Aβ42. Nevertheless, because Aβ42 can also be cleared or
degraded through various processes we considered a
scenario wherein Aβ42 levels may appear unchanged by
ELISA assay even though rates of production of Aβ42
could be different, perhaps due to compensatory deg-
radation mechanisms. To address this possibility, we
noted that Aβ42 production results from the cleavage
by γ-secretase and therefore we assessed the levels of
the γ-secretase substrate, the APP C-terminal fragment
(APP-CTF). Here we also observed no difference in theed to assess the quantity of each of these species in the 0, 200 or 500
duce the amount of Aβ42 by half while 200 mkd was ineffective.
ot evident in the 200 mkd group. Error bars represent standard error of
t-tests For all panels, N =14 for 0 mkd TAPP mice, N =16 for 500 mkd
Figure 6 Thiamet-G reduces plaque load in the TAPP mice. A. Representative 6E10 immunohistochemical analysis used to assess amyloid
plaque load in both the cortical and hippocampal regions. B. Quantitative assessment of 6E10 IHC analysis reveals that both 200 and 500 mkd
Thiamet-G is sufficient to reduce the number of amyloid plaques in the cortex. C. 500 mkd Thiamet-G significantly reduced the number of
amyloid plaques in the hippocampus whereas 200 mkd Thiamet-G was ineffective. Error bars represent standard error of the mean (± S.E.M)
and p-values result from student’s unpaired two-tailed t-tests. For all panels, N =12 in each group.
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(Figure 7D). If changes in O-GlcNAc influenced the
rates of Aβ42 production in these cells but such
changes were obscured in our assays by compensating
Aβ42 degradation, then we would expect APP-CTF
levels would differ. The absence of any difference in
APP-CTF levels, or the α:β ratio of CTF fragments,
upon increased O-GlcNAc therefore provides further
support that Aβ42 release and APP processing are un-
affected by increased O-GlcNAc within this cell line.
As a further step to assess the effect of O-GlcNAc levels
on APP processing in cells we used primary hippocampal
neurons, which are a more physiologically relevant cell
culture model. We assessed the levels of Aβ42 in the con-
ditioned media from primary hippocampal neurons
treated with Thiamet-G for 24 hours as well as the levels
of APP-CTF in these same cells. Here, again, we observed
no difference in either of these measures (Figure 7E, F)
while O-GlcNAc levels were, as expected, dramatically in-
creased in these neuronal cultures (Figure 7G). On the
basis of these results, obtained using two distinct cell lines,
20E2 cells and primary neurons, we propose that in-
creased O-GlcNAc does not affect the release of extracel-
lular Aβ42 from cells. While a direct comparison is notpossible between the cell culture studies and in vivo exper-
iments, because the levels of Thiamet-G used here in cell
culture likely exceed those reached in brain during dosing
in water, these findings reasonably suggest there is also no
effect on Aβ processing in the in vivo studies.
Discussion
In the past number of years, the potential role of O-
GlcNAc in AD has gradually gained more attention
because of the fact that the O-GlcNAc modification is ul-
timately derived from cellular glucose. Through the action
of the hexosamine biosynthetic pathway 2-3% of cellular
glucose is converted into UDP-GlcNAc, which is the sugar
donor substrate for OGT [39]. As a consequence, decreased
glucose availability leads to decreased levels of UDP-
GlcNAc and consequently lower protein O-GlcNAcylation.
In this regard, it is notable that one of the early features of
mild cognitive impairment and AD is impaired glucose
utilization [40] in the brain which would result in decreased
O-GlcNAc levels. Decreased expression of glucose trans-
porters 1 (Glut1) and 3 (Glut3) have been found in AD
brains and loss of function mutations in glucose transporter
1 (Glut1) associate with extent of AD pathology [41,42].
Consistent with these observations, AD brain tissues
Figure 7 Thiamet-G treatment of APPSwe-expressing 20E2 cells and primary hippocampal neurons does not alter APP processing.
A. 20E2 cells were treated with Thiamet-G for 16 hours, and then the amount of Aβ42 in the cell culture media, collected at the indicated time points
after the replacement of new culture media, was assessed using an ELISA assay and corrected for the amount of protein in the cell lysates from each
condition. This analysis reveals that Thiamet-G does not alter the amount of Aβ42 that is produced. B. Little Aβ42 is detected in untransfected human
embryonic kidney (HEK) cells indicating that validity of this culture model. C. O-GlcNAc levels in the 20E2 cells are increased at all time points analyzed
(*indicates p <0.05, paired two-tailed t-test). D. Levels of APP-CTF were unchanged in 20E2 cells treated with Thiamet-G for 24 hours. E. Aβ42 production
is not altered in primary hippocampal neurons treated with Thiamet-G for 24 hour. F. APP-CTF levels are unchanged in 24 hour Thiamet-G treated
hippocampal neurons. G. O-GlcNAc levels in primary hippocampal neurons are increased after 24 hours of treatment with Thiamet-G. (***indicates
p <0.001,, paired two-tailed t-test) Error bars represent standard error of the mean (± S.E.M). N.S. Not Significant. For all panels, N =3.
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estingly, another disease where glucose utilization is im-
paired, diabetes, is a major risk factor for AD [44].
Together, these ideas suggest that O-GlcNAc may play a
protective function in the healthy brain and loss of O-
GlcNAc in AD brain could compromise such protective
mechanisms.
Until recently, the role of O-GlcNAc in AD focused
exclusively on the O-GlcNAcylation of tau and its inter-
play with tau phosphorylation and tau aggregation
[20,26,43,45-47]. While analysis of the data from our long-
term studies were underway a report on the role of O-
GlcNAc on APP and β-amyloid was published, which
made use of an earlier generation OGA inhibitor, NButGT
[48], to increase O-GlcNAc levels in the 5xFAD mouse
model [49]. NButGT is less potent (Ki = 600 nM) and se-
lective (800-fold over functionally related β-N-acetylgluco-
saminidases) as well as less stable than Thiamet-G [26].
Thiamet-G therefore offers some advantages in long term
studies in AD mouse models because it can be added to
the drinking water of treated animals, thereby offering a
simple dosing protocol. The 5xFAD mice studied by Kim
et. al express five different early-onset AD mutations in
human APP along with presenilin 1 but do not develophyperphosphorylated tau or tau aggregates [50]. The
5xFAD mice are therefore a suitable model to study β-
amyloid pathology independent of significant tau path-
ology. In these 5xFAD mice Kim et al. report that
increased O-GlcNAc blocks memory impairment and
results in fewer amyloid plaques. Their data are gener-
ally in good agreement with our data described here. We
find prevention of memory impairment by increased O-
GlcNAc is independent of tau phosphorylation as we ob-
served no changes in tau phosphorylation. However, in
order for this to be definitively proven Thiamet-G treat-
ment of the parental Tg2576 line, which only displays
amyloid pathology, would be necessary. Indeed, this would
be a useful future endeavor to further clarify the role of
O-GlcNAc on amyloid pathology.
Our data described here, with respect to tau pathology,
are in general agreement with our previous studies using
the single transgenic JNPL3 mice. In that work, we found
that Thiamet-G did not block tau hyperphosphorylation
but reduced the number of NFTs and the amount of sar-
kosyl insoluble tau [20]. In the TAPP mice studied here,
we observe no changes in tau hyperphosphorylation but
find a strong trend toward less sarkosyl insoluble tau in
Thiamet-G treated animals. The fact that this finding did
Yuzwa et al. Molecular Neurodegeneration 2014, 9:42 Page 9 of 14
http://www.molecularneurodegeneration.com/content/9/1/42not reach statistical significance might be the result of a
number of different factors. First, the TAPP mice are
known to produce enhanced tau pathology as compared
to similarly aged JNPL3 mice and this aggressive model
may overwhelm or compromise the ability of the O-
GlcNAc modification to impair tau aggregation [17]. Sec-
ondly, the JNPL3 mice display well characterized variable
penetrance of the transgene leading to only ~50% of ani-
mals displaying hyperphosphorylated tau at advanced ages
[51], which decreases the statistical power of the study.
In any event, the use of two OGA inhibitors and the
concordance of results regarding β-amyloid pathology and
cognitive impairment from our study in the dual path-
ology TAPP mice, along with the data collected from the
single pathology 5xFAD mice studied by Kim et al., pro-
vides compelling data that increased O-GlcNAc plays a
pronounced role in hindering the development of β-
amyloid pathology. The findings also collectively indicate
that OGA inhibition is able to influence β-amyloid path-
ology either in the presence or absence of tau pathology.
The observation that 200 mkd Thiamet-G treatment
was sufficient to reduce the number of amyloid plaques
in the cortex of treated TAPP mice while leaving the
amounts of Aβ40 or Aβ42 unchanged is interesting. The
variation in the effects observed from these different
doses may be due to varying levels of O-GlcNAc on dif-
ferent proteins between these two dose groups. Perhaps
only at high doses of Thiamet-G, for extended time pe-
riods, are influences on β-amyloid peptide levels appar-
ent. Lower doses of Thiamet-G may block only amyloid
plaque deposition or influence its clearance. While the
dosing of Thiamet-G in water, coupled with the lack of
knowledge regarding the pharmacokinetics for Thiamet-
G and the lack of detailed knowledge regarding the
pharmacodynamic responsive of O-GlcNAc, make it dif-
ficult to know how specific O-GlcNAc levels influence
these markers, we nevertheless see some evidence for a
dose dependent response in O-GlcNAc levels to support
this idea. Further supporting this idea, in the 20E2 cell
model of APP processing, we do not observe a reduction
in the amounts of Aβ42 released. Kim et al. suggest that
increased O-GlcNAc levels could impair γ-secretase ac-
tivity in CHO cells expressing APPSwe, leading to in-
creased quantities of the membrane bound APP-CTF.
However, the quantities of Aβ40 and Aβ42 were not de-
termined, making direct comparisons with our study dif-
ficult. Another recent study found a non-selective OGA
inhibitor increased O-GlcNAc levels in wild-type SH-
SY5Y cells and this correlated with decreased Aβ40 re-
lease though Aβ42 levels were not evaluated [29]. Given
the established off-target effects of PUGNAc and its abil-
ity to affect levels of cellular gangliosides as well as
intracellular free oligosaccharides [48,52,53] these data
should be interpreted with some caution. Given theseobservations, to further probe this question of the effects
of O-GlcNAc levels on Aβ42 processing, we also evalu-
ated levels of the γ-secretase substrate (APP-CTF) and
product (Aβ42) in two separate models, the standard
20E2 cultured cell model noted above but also in pri-
mary hippocampal neurons since these are a more
physiologically relevant model. In all these experiments,
we observed no effect of Thiamet-G treatment on levels
of Aβ42 released from cells, nor on levels of APP-CTF.
This is a particularly interesting observation in the light of
the fact that lower levels of Aβ42 are observed in Thiamet-
G treated TAPP mice yet we observe no impairment of
APP processing in cells. In this regard we hypothesize that
increased O-GlcNAc levels could result in increased clear-
ance of Aβ peptides or oligomers through various processes
known to contribute to Aβ clearance, or perhaps by redu-
cing neuroinflammation, which could lead to decreased tau
and amyloid pathologies.
Nevertheless, these studies, combined with the literature
noted just above, collectively reveal there is a need for fur-
ther research to define the possible roles O-GlcNAc might
play in APP processing. The clear effect of OGA inhibition
on amyloid pathology in two different models using re-
lated, yet different, compounds also collectively provides a
strong rationale for research studying how O-GlcNAc
might influence plaque assembly and β-amyloid clearance.
Such results could help in a more immediate way to define
novel therapeutic avenues to address the growing problem
of AD associated with aging populations.
Conclusion
Here we have shown that Thiamet-G treatment of TAPP
mice increases O-GlcNAc levels in the brain and com-
pletely prevents cognitive decline. Further, we have
shown that this blockade in cognitive decline is not
likely due to changes in tau hyperphosphorylation or tau
aggregation but rather due to alteration in the release or
clearance of β-amyloid peptides, which are reflected in
the number of amyloid aggregates and plaques. Using a
cellular model of APP processing we have shown that
Thiamet-G does not impair release of β-amyloid pep-
tides from APP and thus likely does not directly regulate
APP processing, suggesting that O-GlcNAc probably
acts at multiple other points in the β-amyloid patho-
logical cascade. Nevertheless, OGA inhibition has posi-
tive effects on β-amyloid pathology in TAPP mice that
develop synergistic tau and β-amyloid pathologies as
shown here. This observation is consistent with observa-
tions made by Kim et al. in 5xFAD mice [49]. Because
these mice display only amyloid pathology, the concordance
of these results in different models strongly supports the
hypothesis that O-GlcNAc exerts positive effects on β-
amyloid pathology whether tau pathology is present or not,
making the molecular mechanisms by which O-GlcNAc
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GlcNAc to influence both tau pathology, as we have previ-
ously shown [20,46] and more recently others [54,55], as
well as β-amyloid pathology, makes OGA a potential thera-
peutic target of considerable interest since OGA inhibitors
may be able to protect against both pathologies and serve
as a monotherapy for altering disease progression in AD.
Methods
Animals
All animal studies were approved by the Simon Fraser
University Animal Care Committee. 60 female double
transgenic APPSwe-Tau (TAPP) mice were purchased
and received from Taconic Farms at 9-12 weeks of age.
10 age-matched wild-type control animals were also ob-
tained from Taconic Farms. The animals were allowed to
acclimatize to the facility for one week after which dos-
ing with OGA inhibitor was started. Thiamet-G was de-
livered to the treatment groups (n = 20) by including the
compound in the drinking water such that each animal
received either 200 or 500 mg/kg/day (mkd) based on an
average water consumption of 4 mL/day/animal. Control
TAPP mice (n = 20) and wild-type (n = 10) received free ac-
cess to regular drinking water which averaged 4 mL/day.
Following the completion of the study when mice were
aged 44 to 47 weeks, both TAPP and wild-type mice
were euthanized using CO2 and perfused transcardially
with 15 mL of PBS (pH 7.4). Brains were dissected from
mice immediately after they were euthanized in order to
minimize post-mortem delay. Each brain was then divided
along the midline to separate the left and right hemi-
spheres. For soluble β-amyloid ELISAs, one hemisphere of
brain was further microdissected into cortex, hippocam-
pus, cerebellum and brainstem, quickly frozen in liquid ni-
trogen, and stored at –80°C until required. For amyloid
plaque immunohistochemistry studies, the other hemi-
sphere of the brain was post-fixed in 4% (w/v) parafor-
maldehyde (PFA, pH 7.4) for 24 h and then transferred
to 20% (w/v) sucrose overnight for cryoprotection after
which the tissue was embedded in optimal cutting
temperature (OCT) embedding medium (Sakura Finetek
USA Inc), and finally sectioned in the sagittal plane (30
μm) using a Leica cryostat.
Behavioral testing
All mice were between 30-32 weeks old at the beginning
of Morris water maze (MWM) testing. For five consecu-
tive days prior to testing, the mice were removed from
their cage, placed in an open cage on a table similar to
the one being used to hold the animals during the test-
ing stage. The animals were allowed to roam freely for 5
minutes and were gently handled as they would be dur-
ing the testing to reduce any stress from these proce-
dures [56]. This pre-test handling was done in thecolony room. On the day of testing, the mice were removed
from the colony room and taken to the testing room.
A 150 cm diameter pool was centered within a rect-
angular room measuring 470 cm × 400 cm, with a video
camera (Sony DCR-SR85) centered overhead; behavior
in the pool was tracked and quantified from the video
feed using AnyMaze software (Stoelting). The walls of the
room were affixed with various geometric symbols. The
pool was filled with water at 23 ± 1°C and made opaque
with non-toxic acrylic white paint. For analysis purposes,
the pool was divided by the software into 4 equal imagin-
ary quadrants, arbitrarily identified as northwest (NW),
northeast (NE), southwest (SW) and southeast (SE). A
hidden escape platform, approximately 25 cm2 and 2.5 cm
below the water surface was randomly placed in the mid-
dle of the SE quadrant, and left in that location for the en-
tirety of the testing period. For other analyses (described
below), the maze was divided into 3 imaginary concentric
rings: an inner ring, a middle ring, which contained the
platform, and an outer ring along the wall.
Each animal was tested four times per day for five
days. The animals were released into the pool from each
of 4 starting locations every day in a pattern that was
randomly determined prior to testing. For every trial, the
animal was placed in the pool facing the wall. Animals
were then allowed 90 seconds to find the platform. If
they were unable to find the platform in that time, they
were guided to it by hand. After allowing each animal to
remain upon the platform for 15 seconds, they were re-
moved. A minimum of 5 minutes elapsed between trials,
during which time the animal was placed on an elevated
platform in the testing room. A heat lamp was affixed
above the platform. All testing started at noon, and the
order in which the animals were tested was randomly
changed, to prevent any time of day effects. For each trial,
data was collected for total time spent in each quadrant or
ring, distance covered, and swim speed. Time spent in the
outer ring (thigmotaxis) was analyzed as a measure of anx-
iety in the maze.
One week following the final test of the acquisition
phase, animals were returned to the MWM for one final
(probe) test, with all animals starting from the same
pre-determined starting location. The platform was re-
moved from the water during this trial, however, and
the amount of time spent over the previous location of
the platform was measured as an indicator of long-term
memory formation.
Tissue culture
20E2 cells are a stable Human embryonic kidney (HEK)
cell line which expresses the Swedish mutation (K670N/
M671L) in the 695 amino acid isoform of APP [37].
20E2 cells were kindly provided by Dr. Weihong Song
(University of British Columbia). Cells were cultured in
Table 1 Antibodies used in this study
Antibody Epitope 2nd Ab
species
Dilution Supplier
RL2 O-GlcNAc Mouse 1:1000 Abcam
CTD110.6 O-GlcNAc Mouse 1:1000 Covance
pS199 Tau-pS199 Rabbit 1:1000 Biosource
pS396 Tau-pS396 Rabbit 1:1000 Biosource
pT212 Tau-pT212 Rabbit 1:1000 Biosource
AT8 Tau-pS202/pT205 Mouse 1:1000 Thermo
AT180 Tau-pT231 Mouse 1:1000 Thermo
PHF-1 Tau-pS396/pS404 Mouse 1:1000 Dr. Peter Davies
12E8 Tau-pS262/pS356 Mouse 1:1000 Thermo
6E10 Amino acids 1-16
of β-amyloid
Mouse 1:1000 In-house at NYIBR
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ing high glucose and 1.5 g/L sodium bicarbonate sup-
plemented with 10% fetal bovine serum (FBS, Gibco).
Cells were maintained in a humidified 37°C incubator
with a 5% CO2 atmosphere. For the time course of β-
amyloid production, 20E2 cells were plated onto 6 well
plates. Thiamet-G was added 16 hours prior to the
start of the experiment and upon initiation of the ex-
periment the media was changed and Thiamet-G was
maintained in the media to maintain continuous ex-
posure. This is to ensure that O-GlcNAc levels were el-
evated prior to starting the experiment and maintained
during the entire experiment. After completion of the
experiment, the media was collected and the cells were
removed from the plates by scraping. Cells were then
pelleted by centrifugation (800 × g) for 5 min, gently
washed once with PBS, and lysed using 1% SDS in PBS
and heated at 95°C for 10 min. The cell lysates and the
media samples were then either used immediately or
aliquoted and stored at –80°C until required. The tis-
sue culture media was then assayed for β-amyloid con-
tent by using the commercial ELISA assays described
below.
Rat primary hippocampal neurons were prepared exactly
as described previously [57] and cultured in primary
neuron growth media (PNGM; Lonza). The astrocyte
feeder layer for the neuronal co-culture was generated
using neural progenitor cells as described [58]. A 50% vol-
ume media replacement was performed before neurons
were treated with vehicle or 100 μM Thiamet-G for 24 hrs.
Immunohistochemistry
Free-floating brain sections were rinsed with PBS (pH
7.4) three times for 45 min first, then permeabilized with
PBS containing 0.3% Triton X-100 (PBST) for 30 min.
After blocking with 10% normal goat serum (NGS) and
2.5% BSA in PBST for 60 min, sections were incubated
with mouse IgG monoclonal anti-β-amyloid antibody
(6E10) at 4°C overnight, which reacts to human Aβ pep-
tide (1-16 aa) and was generated in-house at the NYIBR
and used at a dilution of 1:1000. After washing three
times with PBS for 45 min, sections were incubated with
Alexa488 goat anti mouse IgG (Invitrogen) secondary
antibody at 1:1000 for 90 min. After 45 min washing, the
sections were mounted on pre-coated slides (Adhesion
superfrost plus, Brain Research Laboratories, Newton,
MA), and cover-slipped with Vectashield MountingMe-
dium (H-1000, Vector Laboratories). Sections examined in
parallel but without being exposed to primary antibody
served as experimental controls. The stained sections were
examined using a Nikon C1 confocal system equipped
with Nikon 90i fluorescent microscope. The images were
acquired by the Nikon digital camera and Nikon C1 im-
aging system.Aβ40 and Aβ42 ELISAs
Commercially available enzyme linked immunosorbant
assay (ELISA) kits for amyloidogenic β-amyloid 1-40 and
1-42 (Aβ40 and Aβ42) (Invitrogen) were used to deter-
mine the total human Aβ40 and Aβ42 levels in the brain
homogenates. Aβ42 was detected in neuronal cell cul-
ture media exactly as described by the manufacturer’s
instruction using an ELISA kit from Wako (Human/Rat
β-Amyloid(42)). Protein concentrations of the brain homog-
enates were determined using the BCA method (Pierce)
and the Aβ40 and Aβ42 concentrations were expressed as
ng Aβ40 or Aβ42/g of protein in the homogenate.
Quantitative immunohistochemistry of amyloid
plaques (APs)
One sagittal section per mouse was immuno-stained
with 6E10 which recognizes amino acids 1-16 of β-
amyloid. Immuno-positive APs were counted manually
and expressed as the number of APs/section.
Immunohistochemical staining
Frozen mouse brain sections (50 μm) stored in DeOlo-
mos buffer at -20°C were washed with TBS and treated
with 1% H2O2 and 50% methanol for 30 min to inacti-
vate endogenous peroxidase. After being blocked with
5% normal goat serum in TBS for 1 hour, sections were
incubated with the appropriate primary antibodies (see
Table 1), followed by biotin-labeled secondary antibodies
(Vector Laboratories), HRP-labeled avidin-biotin com-
plex (Vector Laboratories), and the substrate DAB (3,3'-
Diaminobenzidine, Sigma). The specimens were observed
under a microscope (Nikon) and images captured using a
digital camera DS-L2 (Nikon).
Antibodies
All antibodies used in this study are described in the
Table 1.
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Phosphorylated tau was visualized in sagittal brain sec-
tions from 6-9 mice each group by IHC staining. Using
the identical microscope and camera settings, at least four
digital images per sample were taken to reflect the overall
staining in the pons region of brain. For the cortex and
hippocampus, images at 20X were used. Only one image
for hippocampus and one for frontal cortex were taken.
All images were analyzed using the commercially available
software program Image-Pro Plus version 4.0 for Win-
dows (Media Cybernetics, Silver Spring, MD). The total
immuno-intensity of the selected immuno-positive area
was divided by the area size, and the values relative to that
of the 0 mkd TAPP group are presented in the graphs.
The proposed method allowed numerical analysis of the
immunostaining intensity. The data from each group was
normalized by the 0 mkd TAPP group.
Statistics analysis
For the MWM testing repeated measures analysis of vari-
ance (RM-ANOVA) was used to examine the effects of
Thiamet-G on the latency of mice to complete the maze,
their distance traveled, their speed of movement, and their
time in each of the quadrants, with Tukey’s post-hoc to de-
termine group differences where appropriate. The probe
trial was analyzed using a one-way ANOVA with Tukey’s
post-hoc tests. For all other data two-tailed unpaired stu-
dent’s t-tests were used except for the sarkosyl insoluble
tau data where we had data from previous studies to in-
form the predicted direction of change thus allowing the
use of a one-tailed test in this case.
Western blotting
Brain tissue was homogenized at 4°C in 9 volumes of
buffer (Buffer H) containing (50 mM Tris-HCl (pH 7.4),
20 μM UDP, 0.5 μM PUGNAc, 2 mM sodium othovana-
date, 0.1 M NaF, 1.0 mM EGTA, 0.5 mM AEBSF, 2.0 μg/ml
aprotinin, 10 μg/ml Leupeptin, 2.0 μg/ml pepstatin A) and
the protein concentrations of the homogenates were deter-
mined using the BCA method (Pierce). The levels of global
O-GlcNAcylation (CTD110.6 and RL2) and tau phosphor-
ylation at various sites were determined by Western blot
analysis using the antibodies listed in Table 1. Primary neu-
rons were lysed in RIPA buffer containing Complete Prote-
ase Inhibitor Cocktail (Roche). Samples (10 μg) were
resolved on 16% SDS-polyacrylamide gels and transferred
to nitrocellulose membranes for blotting of APP-CTF.
30 μg of protein lysates was loaded per lane of a 4-20%
SDS-polyacrylamide gel for blotting of O-GlcNAcylation
(CTD110.6). Membranes were incubated with the fol-
lowing primary antibodies overnight at 4°C: anti-APP-CTF
(1:2500, Abcam), anti-O-GlcNAc antibody (CTD110.6,
1:3000, Covance) and anti-actin (1:1000; Li-Cor). Quantita-
tive analysis of immunoreactivity was carried out usingimages obtained by Li-Cor fluorescence and quantified
using ImageJ. Quantitation of the lysate concentrations was
performed using the BioRad QuickStart Bradford assay for
both neurons and the 20E2 cells and levels of proteins
established as a ratio of protein to actin.
Sarkosyl extraction
Whole tissue homogenates described above were first cen-
trifuged at 10,000 × g in an Eppendorf 5417C centrifuge for
20 min. Supernatants were adjusted to have a final concen-
tration of 1% N-laurylsacrosinate (Sarkosyl, Sigma) and
were incubated at 37°C for one hour with shaking. Samples
were then centrifuged at 100,000 × g in a Beckman TLA-
45 rotor in a Beckman TL-100 centrifuge at 4°C for 45
min. The supernatant was removed and the sarkosyl insol-
uble pellet was resuspended in SDS-PAGE loading buffer.
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